2026-04-13T01:31:33Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1738602025-11-20T15:11:25Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Jove, Maria author Vilariño, Noelia author Nadal, Ernest author 2021-02-12T07:36:48Z 2021-02-12T07:36:48Z 2019-12-01 2021-02-08T10:13:14Z Immune checkpoint inhibitors (ICI) have become part of the standard of care of patients with locally advanced and advanced non-small cell lung cancer (NSCLC) (1). Corticosteroids are broadly used as premedication for most chemotherapy regimens and are frequently used to alleviate pain or dyspnea, to stimulate appetite, or to palliate symptoms associated with brain or epidural metastases. However, corticosteroids have anti-inflammatory and immunosuppressive effects that act over both innate and adaptive immunity. Based on this, patients treated with corticosteroids at doses equal to or higher than 10 mg/day of prednisone or equivalent have been systematically excluded from clinical trials of ICI. Càncer de pulmó Mestàstasi Lung cancer Metastasis Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer